Feasibility Study of an Innovative Medical Device for Sampling the Contents of the Small Intestine. Functional Evaluation on the Transit of Healthy Volunteers. A First in Man, Prospective, Monocentric, Not Randomized Study.
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- Healthy Volunteers
- Sponsor
- University Hospital, Grenoble
- Enrollment
- 16
- Locations
- 1
- Primary Endpoint
- Demonstrate the absence of adverse events (safety of the medical device) and that the device is analyzable (performance of the medical device).
- Status
- Completed
- Last Updated
- 8 months ago
Overview
Brief Summary
For the first time in the world, the objective of this study is to evaluate on healthy volunteers, an innovative medical device for the capture of intestinal liquid.This medical device is not yet CE marked.
Detailed Description
This medical device consists of a standard pill made of 3 capsules for the collection of intestinal microbiota. The pill is ingested by the volunteer and multi-omics analysis will be performed on intestinal fluid samples from the capsules and also on faeces. First in man, involving a medical device, prospective, monocentric, not randomized, not controlled and open-label study.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Able to understand the study and the associated instructions
- •Aged ≥18 years and ≤65 years
- •Fasting with water and food for at least 10 hours
- •BMI between ≥20 and ≤30 kg/m².
- •Transit evaluated at 1 to 3 bowel movements/day
- •Maintain regular physical activity and eating habits for the duration of the study
- •Affiliated with a social security plan
- •Have a freezer in their home and at work, if applicable
- •Volunteer staying in the Isère department during the collection of the faeces (from 96 hours to 15 days max)
- •Having signed the informed and collection consent
Exclusion Criteria
- •with medical treatment (except oral contraception and/or probiotics and related products)
- •with lactose and fructose intolerance
- •with of gastroparesis
- •who had a colonoscopy preparation up to 1 month prior to inclusion
- •in the exclusion period of another clinical investigation,
- •who receive more than 4500 euros of compensation due to his participation in other biomedical research in the 12 months preceding this study
- •who cannot be contacted in case of emergency
- •who has taken during the 15 days prior to inclusion and/or is scheduled to take the following treatments during the study: antidepressants, anxiolytics, antiparkinsonian agents, neuroleptics, antibiotics and prebiotics
- •who has taken during the previous 7 days: at least once a treatment for irritable bowel syndrome (antispasmodics,..) or for constipation (laxative) or for diarrhea
- •with a known food allergy
Outcomes
Primary Outcomes
Demonstrate the absence of adverse events (safety of the medical device) and that the device is analyzable (performance of the medical device).
Time Frame: From 96 hours to 15 days
Safety is assessed with the absence of grade \>3 adverse events. Performance is assessed by the presence of at least one capsule found in the stool with a satisfactory visual condition of capsule and with a sufficient volume of its contents within 96 hours after ingestion. The primary objective of this study is met if safety and performance are achieved for at least 12 of 15 volunteers.
Secondary Outcomes
- Verify that the medical device has captured intestinal fluid(From 96 hours to 15 days)
- Number and grade of adverse events collected during the capsule collection period(From 96 hours to 15 days)
- Number of capsules found to verify that the medical device passes through the human body(From 96 hours to 15 days)
- Obtain an overview of the sample's functional potential and identify biomarkers (organisms) via culturomics, on samples from up to 2 subjects.(From 96 hours to 2 months)
- Metagenomic analysis using 16s sequencing will provide data to establish differences in the gut microbiota profile/composition between capsule and faecal contents.(From 96 hours to 15 days)
- Absence of tears and detachment of the various elements of the capsule(From 96 hours to 15 days)
- Medical device usability and acceptability : descriptive analysis(From 96 hours to 15 days)
- Verify that the medical device has opened in the intestine(From 96 hours to 15 days)